Caribou Biosciences, Inc. (CRBU)
|Net Income (ttm)||-37.67M|
|Day's Range||23.05 - 25.60|
|52-Week Range||15.00 - 32.65|
|Price Target||30.67 (+27.0%)|
|Est. Earnings Date||Nov 11, 2021|
Caribou Biosciences is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying our novel CRISPR platform, chRDNA toward the development of next-generation, genome-edited cell therapies. We believe that our technology has broad potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell therapies, cell therapies derived from genome-edited iPSCs, and in vivo genome-editing therapies. We are initially focused on ad... [Read more...]
Financial PerformanceFinancial Statements
Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary ...
Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou's proprietary chRDNA technology for therapeutic applications
BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appoin...
BERKELEY, Calif.--(BUSINESS WIRE)---- $CRBU--Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previ...
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap.
BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering...
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Al...
BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-...
In a filing with SEC on Thursday, Caribou Biosciences (NASDAQ: CRBU) is penciling in a $100 million initial public offering. The firm expects that its new shares will trade on the NASDAQ under the symbo...
Caribou Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.